medigraphic.com
ISSN 0016-3813 (Impreso)

2019, Número 5

<< Anterior Siguiente >>

Gac Med Mex 2019; 155 (5)


Descubrimiento de la proteína reguladora de apoptosis 2 como determinante en la muerte de células tumorales

Tapia-Vieyra JV, Mas-Oliva J

Idioma: Español
Referencias bibliográficas: 49
Paginas: 546-553
Archivo PDF: 1665.17 Kb.


RESUMEN

El cáncer es una enfermedad multifactorial que constituye un problema de salud pública mundial. Las etapas avanzadas del cáncer de próstata están asociadas con el desarrollo de tumores independientes de andrógeno y un fenotipo resistente a la apoptosis que progresa a metástasis. Al estudiar células de cáncer de próstata de nódulo linfoide (LNCaP) independientes de andrógeno inducidas a la apoptosis por eliminación de suero, identificamos la activación de un canal catiónico no selectivo de 23pS de conductancia que promueve corrientes entrantes de Ca2+ así como las etapas finales de la apoptosis. El cDNAarp2 fue aislado e identificado del mismo tipo celular y el ARN mensajero fue expresado en ovocitos de Xenopus laevis, asociándolo con la activación de las corrientes entrantes de Ca2+ y la inducción a la apoptosis. El ADN complementario que codifica para la proteína reguladora de apoptosis 2 (ARP2) fue sobreexpresado en células LNCaP y células de ovario de hámster chino, induciendo apoptosis. Nuestra evidencia sugiere que la sobreexpresión y tránsito de la proteína ARP2 a la membrana celular permite una corriente de entrada de Ca2+ aumentada, iniciadora del proceso de apoptosis en células de tipo epitelial cuyo fenotipo muestra resistencia a la muerte celular programada.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Vineis P, Wild CP. Global cancer patterns: causes and prevention. Lancet. 2014;383:549-557.

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.

  3. Hossein-Hassanpour S, Dehghani M. Review of cancer from perspective of molecular. J Cancer Res Pract. 2017;4:127-129.

  4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7-30.

  5. Schottenfeld D, Fraumeni JF. Cancer epidemiology and prevention. Inglaterra: Oxford Scholarship Online; 2006.

  6. Yoo KY, Shin HR. Cancer epidemiology and prevention. Korean J Epidemiol. 2003;25:1-15.

  7. Pinton P, Giorgi C, Siviero R, Zecchini E, Rizzuto R. Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis. Oncogene. 2008;27:6407-6418.

  8. Gutiérrez AA, Arias JM, García L, Mas-Oliva J, Guerrero-Hernández A. Activation of a Ca2+ permeable cation channel by two different inducers of apoptosis in a human prostatic cancer cell line. J Physiol. 1999;15:95-107.

  9. Tapia-Vieyra JV, Arellano RO, Mas-Oliva J. ARP2 a novel protein involved in apoptosis of LNCaPcells shares a high degree homology with splicing factor Prp8. Mol Cel Biochem. 2005;269:189-201.

  10. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-E386.

  11. Dall’Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, et al. 2012. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012;62:976-983.

  12. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29.

  13. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215-224.

  14. Talcott JA. In the clinic. Prostate cancer. Ann Intern Med. 2015;163:ITC1- ITC12.

  15. Quinn DI, Sandler HM, Horvath LG, Goldkorn A, Eastham JA. The evolution of chemotherapy for the treatment of prostate cancer. Ann Oncol. 2017;28:2658-2669.

  16. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-257.

  17. Tapia-Vieyra JV, Delgado-Coello B, Mas-Oliva J. Atherosclerosis and cancer; a resemblance with far-reaching implications. Arch Med Res. 2017;48:12-26.

  18. Chen M, Wang J. Initiator caspases in apoptosis signaling pathways. Apoptosis. 2002;7:313-319.

  19. Cooper KF. Till death do us part: the marriage of autophagy and apoptosis. Oxidative Med Cell Longevity. 2018;1:1-13.

  20. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25:4798-4811.

  21. Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014;2014:150845.

  22. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495-516.

  23. Adams JM. Ways of dying: multiple pathways to apoptosis. Genes Dev. 2003;17:2481-2495.

  24. Mason RP. Calcium channel blockers, apoptosis and cancer: is there a biologic relationship? J Am Coll Cardiol. 1999;34:1857-1866.

  25. Clapham DE. Calcium signaling. Cell. 2007;131:1047-1058.

  26. Rizzuto R, Pinton P, Ferrari D, Chami M, Szabadkai G, Magalhães PJ, et al. Calcium and apoptosis: facts and hypotheses. Oncogene. 2003;22:8619-8627.

  27. Giorgi C, Romagnoli A, Pinton P, Rizzuto R. Ca2+ signaling, mitochondria and cell death. Curr Mol Med. 2008;8:119-130.

  28. Fariss MW, Pascoe GA, Reed DJ. Vitamin E reversal of the effect of extracellular calcium on chemically induced toxicity in hepatocytes. Science. 1985;227:751-754.

  29. Pinton P, Rizzuto R. Bcl-2 and Ca2+ homeostasis in the endoplasmic reticulum. Cell Death Differ. 2006;13:1409-1418.

  30. Görlach A, Bertram K, Hudecova S, Krizanova O. Calcium and ROS: a mutual interplay. Redox Biol. 2015;6:260-271.

  31. Tapia-Vieyra JV, Mas-Oliva J. Apoptosis and cell death channels in prostate cancer. Arch Med Res. 2001;32:175-185.

  32. Schamberger CJ, Gerner C, Cerni C. Caspase-9 plays a marginal role in serum starvation-induced apoptosis. Exp Cell Res. 2005;302:115-128.

  33. Braun F, Bertin-Ciftci J, Gallouet AS, Millour J, Juin P. Serum-nutrient starvation induces cell death mediated by Bax and Puma that is counteracted by p21 and unmasked by Bcl-xL inhibition. PlosOne. 2011;6:e23577.

  34. Kelemen O, Convertini P, Zhang Z, Wen Y, Shen M, Falaleeva M, et al. Function of alternative splicing. Gene. 2017;514:1-30.

  35. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem. 2003;72:291-336.

  36. Blencowe BJ. Alternative splicing: new insights from global analyses. Cell. 2006;126:37-47.

  37. Bellare P, Kutach AK, Rines AK, Guthrie C, Sontheimer EJ. Ubiquitin binding by a variant Jab1/MPN domain in the essential pre-mRNA splicing factor Prp8p. RNA. 2006;12:292-302.

  38. Bhuyan AK, Varshney A, Mathew MK. Resting membrane potential as a marker of apoptosis: studies of xenopus oocytes microinjected with cytochrome c. Cell Death Differ. 2001;8 63-69.

  39. Braun T, Dar S, Vorobiov D, Lindenboim L, Dascal N, Stein R. 2003. Expression of Bcl-x(S) in xenopus oocytes induces BH3-dependent and caspase-dependent cytochrome c release and apoptosis. Mol Cancer Res. 2003;1:186-194.

  40. Boulay G, Zhu X, Peyton M, Jiang M, Hurst R, Enrico S, et al. Cloning and expression of a novel mammalian homolog of Drosophila transient receptor potential (Trp) involved in calcium entry secondary to activation of receptors coupled by the Gq class of G protein. J Biol Chem. 1997;272:29672-29680.

  41. Mas-Oliva J, Navarro-Vidal E, Tapia-Vieyra JV. ARP2, a novel pro-apoptotic protein expressed in epithelial prostate cancer LNCaP cells and epithelial ovary CHO transformed cells. PLoS One. 2014;9 e86089.

  42. Wang D, Nguyen MM, Masoodi KZ, Singh P, Jing Y, O’Malley K, et al. Splicing factor Prp8 interacts with NES(AR) and regulates androgen receptor in prostate cancer cells. Mol Endocrinol. 2015;29:1731-1742.

  43. Sato N, Maeda M, Sugiyama M, Ito S, Hyodo T, Masuda A, et al. 2015. Inhibition of SNW1 association with spliceosomal proteins promotes apoptosis in breast cancer cells. Cancer Med. 2015;4:268-277.

  44. Maniatis T, Tasic B. Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature. 2002;418:236-243.

  45. Schwerk C, Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell. 2005;19:1-13.

  46. Moore MJ, Wang Q, Kennedy CJ, Silver PA. An alternative splicing network links cell-cycle control to apoptosis. Cell. 2010;142:625-636.

  47. Krebs J. The influence of calcium signaling on the regulation of alternatives splicing. Biochim Biophys Acta. 2009;1793:979-984.

  48. Tarn WY. Cellular signals modulate alternative splicing. J Biomed Sci. 2007;14:517-522.

  49. Bracco L, Kearsey J. The relevance of alternative RNA splicing to pharmacogenomics. Trends Biotechnol. 2003;21:346-353.




2020     |     www.medigraphic.com